Interstitial collagenases as markers of tumor progression

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4823-4830

  Brinckerhoff, C E ^a   Rutter, J L ^a   Benbow, U ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TUMOR MARKER;

CANCER GROWTH; CANCER INVASION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FIBROBLAST; HUMAN; MELANOMA; METASTASIS; OVARY CANCER; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

BIOLOGICAL MARKERS; COLLAGENASES; DISEASE PROGRESSION; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MODELS, BIOLOGICAL; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0034488852     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Changing views on the role of matrix metalloproteinases in metastasis
2. Matrix metalloproteinases
3. Matrix metalloproteinases in tumor invasion and metastasis
4. Unraveling the role of proteases in cancer
5. Matrix metalloproteinases
6. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
7. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion
8. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
9. A novel host/tumor cell interaction activates matrix metalloproteinase I and mediates invasion through type I collagen
10. Membrane type I matrix metalloproteinase digest interstitial collagens and other extracellular matrix macromolecules
11. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP
12. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
13. Matrix metalloproteinase-2 is an interstitial collagenase
14. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix
15. Regulating expression of the gene for matrixmetalloproteinase-1 (collagenase): Mechanisms that control enzyme activity, transcription and mRNA stability
16. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications
17. Matrix metalloproteinases: Biologic activity and clinical implications
18. Matrix metalloproteinases: Multifunctional contributors to tumor progression
19. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
20. Membrane-type matrix metalloproteinases
21. Immunological characterization of cell-surface and soluble forms of membrane type I matrix metalloproteinase in human breast cancer cells and in fibroblasts
22. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
23. Membrane-type metalloproteinases in tumor invasion
24. Enhancement of membrane-type I-matrix metalloproteinase (MT1-MMP) production and subsequent activation of progelatinase A on human squamous cell carcinoma cells co-cultured with human dermal fibroblasts
25. Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas
26. Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: Expressed in adrenocortical cancers but not in adenomas
27. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlation with tumor invasion and metastasis
28. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx
29. Significance of membrane type I matrix metalloproteinase expression in breast cancer
30. Broad anti-tumor and anti-angiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
31. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis
32. Role of MT-MMPs and MMP-2 in pancreatic cancer progression
33. Expression of messenger RNAs for membrane-type 1, 2 and 3 matrix metalloproteinases in human renal cell carcinomas
34. Expression and tissue localization of membrane types 1, 2 and 3 matrix metalloproteinases in human urothelial carcinomas
35. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells
36. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis
37. Coordinated and cell-specific regulation of membrane type metalloproteinase 1 (MT1-MMP) and its substrate matrix metalloproteinase 2 (MMP-2) by physiologic signals during follicular development and ovulation
38. Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation
39. Gelatinase-A (MMP-2), gelatinase-B (MMP-9), and membrane type matrix metalloprotienase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas
40. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
41. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma
42. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
43. An overview of collagenase-3 expression malignant tumors and analysis of its potential value as a target in antitumor therapies
44. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors
45. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation
46. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds
47. Cloning, expression and type II collagenolytic activity of matrix metalloproteinase 13 from human osteoarthritic cartilage
48. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes
49. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes
50. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB
51. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis
52. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive squamous cell carcinomas
53. Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck
54. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor
55. Collagenase specificity in chondrosarcoma metastasis
56. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas
57. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
58. Transcriptional regulation of the collagenase-1 (matrix metalloproteinase-1; MMP-1) gene
59. The AP-1 site and MMP gene regulation: What is all the fuss about?
60. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
61. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
62. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor
63. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer
64. Matrix metalloproteinase-1 and -3 in breast cancer: Correlation with progesterone receptors and other clinicopathological feature
65. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region
66. 72K-GL (MMP-9) and 92K-GL (MMP-2) are produced in vivo by human oral squamous cell carcinomas and can enhance FIB-CL (MMP-1) activity in vitro
67. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells
68. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas
69. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
70. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription
71. The Ets family of transcription factors
72. Loss of heterozygosity on chromosome 11q.22.23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase 1 promoter
73. Location of several putative genes possibly involved in human breast cancer progression
74. Expression of c-Ets-l, collagenase-1 and urokinase-type plasminogen activator genes in lung carcinomas
75. Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions
76. Expression of c-ets-1 mRNA is associated with an invasive EMT-derived phenotype in breast carcinoma lines
77. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities
78. Erg, an Ets-family member, differentially regulates human collagenase-1 (MMP-1) and stromelysin-1 (MMP-3) expression by physically interacting with the Fos/Jun complex
79. The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner
80. Multidrug resistance - A multiplex phenomenon
81. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression
82. Breast cancer: Cell and gene therapy
83. Intratumor heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma
84. Altered gene expression in drug-resistant human breast cancer cells
85. Therapeutic intervention and signaling
86. The hallmarks of cancer
87. Regulation of matrix metalloproteinase expression in tumor invasion
88. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat
89. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94)
90. Inhibition of matrix metalloproteinases; therapeutic applications
91. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
92. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms
93. Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RAR γ in induction of differentiation and apoptosis in S91 melanoma cells
94. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro and causes cell growth inhibition in xenografts in vivo
95. Retinoid-mediated inhibition of tumor invasion and matrix metalloproteinase synthesis
96. Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid in human breast cancer cells requires distal regions of the promoter
97. Human breast cancer cells activate procollagenase-1 and invade type I collagen: Invasion is inhibited by all-trans retinoic acid
98. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers
99. Expression of retinoic acid receptors in squamous cell carcinoma and their possible implications for chemoprevention
100. All-trans-retinoic acid in acute promyelocytic leukemia
101. Retinoic receptors in human lung cancer and breast cancer
102. Aerolized delivery and lung cancer prevention: Pre-clinical models show promise